高级搜索

PBRM1——肿瘤靶向及免疫检查点治疗的潜在标志物

PBRM1: Potential Biomarker for Tumor Targeted Therapy and Immune Checkpoint Therapy

  • 摘要: PBRM1基因在多种肿瘤中表现为抑癌基因,其突变或表达状态对不同肿瘤预后的评估价值不一。机制研究提示JAK/STAT3,PBRM1/RLR等信号的活化参与了PBRM1激活肿瘤患者免疫功能、诱发炎性反应并启动炎癌转化,从而影响患者生物靶向治疗和免疫检查点治疗的敏感度。免疫检查点抑制剂与靶向药物的联合治疗策略是未来肿瘤治疗的发展趋势。本文分析PBRM1在不同肿瘤患者预后指导中的作用,并阐述PBRM1检测在指导患者对上述药物和治疗策略的选择及疗效评估中的重要意义。

     

    Abstract: PBRM1 appears as a tumor suppressor gene in a variety of tumors. The value of PBRM1 mutation or expression is different for the prognosis prediction of different kinds of tumors. Studies have revealed that JAK/STAT3, PBRM1/RLR and other signals were participated in the process of PBRM1 activating immune system, inflammatory responses and the transform of inflammation to cancer. This process modified the sensitivity of the patients to biological targeted therapy and immune checkpoint therapy. The combination of immune checkpoint inhibitor and targeted drug is the develop trends of cancer therapy in the future. In this review, we discuss the role of PBRM1 in the prognosis guidance of patients with different tumors, and explain the importance of PBRM1 detection in guiding the selection of drugs and treatment strategies and evaluating the efficacy.

     

/

返回文章
返回